Mavacamten (1642288-47-8): A Novel Myosin Modulator for Hypertrophic Cardiomyopathy Treatment
Discover the therapeutic potential of Mavacamten, a breakthrough cardiac myosin modulator for obstructive hypertrophic cardiomyopathy.
Get a Quote & SampleProduct Core Value
Mavacamten
Mavacamten is a cutting-edge small molecule designed to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM). It acts as an allosteric modulator of cardiac myosin, targeting the underlying sarcomere hypercontractility. This innovative approach aims to alleviate symptoms and enhance the daily activity levels of affected patients.
- Research indicates Mavacamten effectively modulates cardiac myosin activity, offering a new avenue for hypertrophic cardiomyopathy therapies.
- This cardiac myosin modulator is available as a refined white powder with a purity of 98%, making it ideal for research and development purposes.
- As a novel pharmaceutical compound, Mavacamten is supplied by reputable manufacturers in China, contributing to global cardiovascular disease treatment efforts.
- Understanding the Mavacamten CAS 1642288-47-8 is crucial for researchers investigating advanced cardiology treatments and for sourcing R&D grade biochemicals.
Key Advantages Offered
Targeted Mechanism
Mavacamten operates as an allosteric modulator of cardiac myosin, providing a precise mechanism for treating HCM by addressing sarcomere hypercontractility.
Symptom Relief
The compound is engineered to not only manage the condition but also to improve a patient's daily symptoms and overall ability to engage in activities.
High Purity for Research
With a 98% purity level, this product is well-suited for sensitive research applications, ensuring reliable results in pharmacological studies.
Key Applications
Cardiovascular Disease Treatment
Mavacamten is a significant advancement in treating cardiovascular conditions, specifically focusing on obstructive hypertrophic cardiomyopathy.
Cardiomyopathy Therapy
This drug represents a novel approach to cardiomyopathy therapy, aiming to restore normal heart function and reduce disease progression.
Research and Development
As a high-purity compound, it is invaluable for ongoing research into cardiac myosin modulators and new therapeutic strategies.
Drug Discovery
Mavacamten serves as a key reference compound in drug discovery programs targeting cardiac muscle disorders and related pathways.